Skip to main
IGMS
IGMS logo

IGMS Stock Forecast & Price Target

IGMS Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 14%
Buy 21%
Hold 57%
Sell 7%
Strong Sell 0%

Bulls say

IGM Biosciences Inc. is positioned favorably within the biotechnology sector, supported by its innovative IgM antibody technology platform, which has the potential to revolutionize treatments for various diseases. The company's collaboration with SNY for developing novel IgM agonists suggests a promising pipeline with nearly $3 billion in potential milestone revenues, reflecting significant financial upside if the candidates prove successful. Furthermore, the differentiated cytokine profile and acceptable safety associated with IgM-based antagonists bolster a positive outlook and could enhance the company's market competitiveness in the rapidly evolving therapeutic landscape.

Bears say

IGM Biosciences Inc. faces significant downside risk primarily due to its inability to advance key internal programs or secure external assets, leading to a potential fair value of $0.50, which is below the cash per share value. The recent decision to discontinue its primary value-driving bispecific T-cell engager clinical pipeline, alongside a substantial workforce reduction, highlights operational challenges and raises concerns about the company's future viability. Compounding these issues are the disappointing efficacy results of its drug candidates, Aplitabart and Imvotamab, and the discontinuation of IGM-2644, further reinforcing a negative outlook amidst ongoing financial instability and high volatility.

IGMS has been analyzed by 14 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 21% recommend Buy, 57% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IGM Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IGM Biosciences Inc (IGMS) Forecast

Analysts have given IGMS a Hold based on their latest research and market trends.

According to 14 analysts, IGMS has a Hold consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IGM Biosciences Inc (IGMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.